期刊
ZEITSCHRIFT FUR GASTROENTEROLOGIE
卷 55, 期 6, 页码 575-581出版社
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0043-102581
关键词
cholangiocarcinoma; biliary tract; genomic background; next generation sequencing; heterogeneity; targeted therapy; immune modulating therapy
The term cholangiocarcinoma (CCA) comprises neoplasms of the intrahepatic, perihilar, and distal bile duct. Five-year survival rates of patients with CCA are below 20 %, and no targeted therapy could prove a benefit in comparison to the standard treatment of cisplatinum and gemcitabine. In recent years, next generation sequencing studies revealed a profound genomic heterogeneity of CCA subtypes potentially affecting the design of future therapy trials. This review provides a concise update on current clinical management of CCA including data of recent genomic studies and differences between CCA subtypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据